Crystal structure of 1,1 -(1,3-propanediyl)bis(4-cyano)pyridiniuiii dibromide, [NC-C5H4N-C3H6-NC5H4-CN]Br2

Por Inkmann E., Holzgrabe U., Schröder D., Reuter H.
Publicado em 1997-12-01

New Semiphysiological Absorption Model To Assess the Pharmacodynamic Profile of Cefuroxime Axetil Using Nonparametric and Parametric Population Pharmacokinetics

Por Bulitta, J. B., Landersdorfer, C. B., Kinzig, M., Holzgrabe, U., Sorgel, F.
Publicado em 2009

Emerging Antimicrobial Drug Resistance in Africa and Latin America: Search for Reasons

Por Hoellein L, Kaale E, Hebron Mwalwisi Y, Schulze MH, Vetye-Maler C, Holzgrabe U
Publicado em 2022-04-01

Comparable Population Pharmacokinetics and Pharmacodynamic Breakpoints of Cefpirome in Cystic Fibrosis Patients and Healthy Volunteers

Por Bulitta, J. B., Kinzig, M., Landersdorfer, C. B., Holzgrabe, U., Stephan, U., Sörgel, F.
Publicado em 2011

Systematic Comparison of the Population Pharmacokinetics and Pharmacodynamics of Piperacillin in Cystic Fibrosis Patients and Healthy Volunteers

Por Bulitta, J. B., Duffull, S. B., Kinzig-Schippers, M., Holzgrabe, U., Stephan, U., Drusano, G. L., Sörgel, F.
Publicado em 2007

Population Pharmacokinetic Comparison and Pharmacodynamic Breakpoints of Ceftazidime in Cystic Fibrosis Patients and Healthy Volunteers

Por Bulitta, J. B., Landersdorfer, C. B., Hüttner, S. J., Drusano, G. L., Kinzig, M., Holzgrabe, U., Stephan, U., Sörgel, F.
Publicado em 2010

Agonists with supraphysiological efficacy at the muscarinic M(2) ACh receptor

Por Schrage, R, Seemann, WK, Klöckner, J, Dallanoce, C, Racké, K, Kostenis, E, De Amici, M, Holzgrabe, U, Mohr, K
Publicado em 2013